Antares Therapeutics and Novartis have entered a strategic oncology collaboration worth up to $1.9 billion to develop small molecule therapies targeting historically undruggable cancer proteins.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
Antares Therapeutics has formed a strategic collaboration with Novartis to discover, develop, and commercialize small molecule therapies targeting historically undruggable cancer proteins. The partnership combines Antares’ proprietary discovery platform with Novartis’ global drug development capabilities to accelerate the development of first-in-class precision medicines for oncology.
Under the agreement, Antares will receive $105 million upfront and may earn up to $1.8 billion in option exercise, development, regulatory, and commercial milestone payments across multiple programs. The company is also eligible to receive tiered royalties on future global net sales.
Leveraging Covalent Drug Discovery for Difficult Cancer Targets
Many cancer-driving proteins remain difficult to target with conventional medicines because they lack suitable binding sites or have complex biological structures. Antares has built a proprietary discovery engine focused on overcoming these challenges through covalent drug discovery.
Its platform integrates specialized screening libraries, chemical proteomics, structure-based computational chemistry, and machine learning to identify highly selective small molecules against previously intractable oncology targets. The collaboration will initially focus on a limited number of these targets while Antares leads early-stage research before Novartis has the option to advance selected programs.
Antares will continue to develop its wholly owned and partnered pipeline of precision medicines for cancer and other serious diseases alongside the collaboration.
Partnership Expands Development Opportunities
During the research phase, Antares will direct discovery activities using its proprietary platform until Novartis exercises its option on individual programs. Following option exercise, Novartis is expected to lead further clinical development, regulatory activities, and global commercialization.
The collaboration reflects growing industry interest in expanding the range of druggable cancer targets through advances in medicinal chemistry, computational biology, and targeted covalent inhibitors.
Leadership Highlights Scientific Strengths
Antares Chief Executive Officer Adam Friedman, MD, PhD, said the collaboration validates the company’s long-term strategy of building a discovery engine capable of consistently generating highly selective medicines against some of the most challenging targets in oncology. He added that combining Antares’ discovery expertise with Novartis’ global development and commercialization capabilities could accelerate delivery of new therapies for patients.
Fiona Marshall, President of Biomedical Research at Novartis, said many of the most promising oncology targets have historically been considered undruggable. She noted that the collaboration could help expand the next generation of targeted cancer therapies by applying innovative drug discovery approaches to these difficult biological targets.
Path Forward
The collaboration begins with Antares leading discovery research across selected oncology programs while Novartis retains future option rights for clinical development and commercialization. As programs advance, Antares could receive substantial milestone payments and royalties while continuing to expand its independent oncology pipeline. The partnership also highlights increasing investment in technologies capable of unlocking historically inaccessible cancer targets and broadening the reach of precision oncology.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.